These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 26847547)

  • 1. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH).
    Nati M; Haddad D; Birkenfeld AL; Koch CA; Chavakis T; Chatzigeorgiou A
    Rev Endocr Metab Disord; 2016 Mar; 17(1):29-39. PubMed ID: 26847547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis.
    Chackelevicius CM; Gambaro SE; Tiribelli C; Rosso N
    World J Gastroenterol; 2016 Nov; 22(41):9096-9103. PubMed ID: 27895397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis.
    Chen Y; Tian Z
    Front Immunol; 2020; 11():1500. PubMed ID: 32765518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update.
    Sutti S; Bruzzì S; Albano E
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):243-53. PubMed ID: 26634783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Hirsova P; Bamidele AO; Wang H; Povero D; Revelo XS
    Front Endocrinol (Lausanne); 2021; 12():760860. PubMed ID: 34777255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity.
    Van Herck MA; Weyler J; Kwanten WJ; Dirinck EL; De Winter BY; Francque SM; Vonghia L
    Front Immunol; 2019; 10():82. PubMed ID: 30787925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease.
    Nati M; Chung KJ; Chavakis T
    J Innate Immun; 2022; 14(1):31-41. PubMed ID: 34515137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating inflammation to combat non-alcoholic fatty liver disease.
    Wiering L; Tacke F
    J Endocrinol; 2023 Jan; 256(1):. PubMed ID: 36259984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression.
    Dallio M; Sangineto M; Romeo M; Villani R; Romano AD; Loguercio C; Serviddio G; Federico A
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33406763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease.
    Katsarou A; Moustakas II; Pyrina I; Lembessis P; Koutsilieris M; Chatzigeorgiou A
    World J Gastroenterol; 2020 May; 26(17):1993-2011. PubMed ID: 32536770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β.
    Hart KM; Fabre T; Sciurba JC; Gieseck RL; Borthwick LA; Vannella KM; Acciani TH; de Queiroz Prado R; Thompson RW; White S; Soucy G; Bilodeau M; Ramalingam TR; Arron JR; Shoukry NH; Wynn TA
    Sci Transl Med; 2017 Jun; 9(396):. PubMed ID: 28659437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies.
    Luci C; Bourinet M; Leclère PS; Anty R; Gual P
    Front Endocrinol (Lausanne); 2020; 11():597648. PubMed ID: 33384662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidized LDL at the crossroads of immunity in non-alcoholic steatohepatitis.
    Houben T; Brandsma E; Walenbergh SMA; Hofker MH; Shiri-Sverdlov R
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Apr; 1862(4):416-429. PubMed ID: 27472963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
    Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
    Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling.
    Barrow F; Khan S; Fredrickson G; Wang H; Dietsche K; Parthiban P; Robert S; Kaiser T; Winer S; Herman A; Adeyi O; Mouzaki M; Khoruts A; Hogquist KA; Staley C; Winer DA; Revelo XS
    Hepatology; 2021 Aug; 74(2):704-722. PubMed ID: 33609303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revisiting the Role of Natural Killer Cells in Non-Alcoholic Fatty Liver Disease.
    Martínez-Chantar ML; Delgado TC; Beraza N
    Front Immunol; 2021; 12():640869. PubMed ID: 33679803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease.
    Carranza-Trejo AM; Vetvicka V; Vistejnova L; Kralickova M; Montufar EB
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):783-796. PubMed ID: 33557653
    [No Abstract]   [Full Text] [Related]  

  • 19. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin.
    Ni Y; Nagashimada M; Zhan L; Nagata N; Kobori M; Sugiura M; Ogawa K; Kaneko S; Ota T
    Endocrinology; 2015 Mar; 156(3):987-99. PubMed ID: 25562616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.